Small Molecules Exporting CUG RNA Foci to Correct Splicing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective strategies to inhibit the aggregation of RNA with expanded trinucleotide repeats, which is a hallmark of polynucleotide repeat disorders such as myotonic dystrophy, leading to severe symptoms and progressive myopathy with no current therapeutic options.
Innovation Solution
Development of specific compounds, such as those of formula (1), (2), and (3), which are administered to subjects to reduce the formation of RNA foci and aggregates by promoting the nuclear export of CUG-rich transcripts, thereby correcting the splicing factor function and alleviating disease symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polynucleotide repeat expansions are present in genes, then RNA aggregates form in the nucleus, but this leads to sequestration of splicing factors and mis-splicing of mRNAs causing disease symptoms
Solution Approach 1:
The patent applies the principle of converting harm into benefit by using compounds that bind to the harmful CUG repeat RNA sequences and convert them into beneficial forms that can be exported from the nucleus. The compounds transform the pathogenic RNA aggregates into export-competent complexes, thereby eliminating the harmful sequestration effect while maintaining the RNA's informational value.
Solution Approach 2:
The patent employs small molecule compounds as intermediaries that mediate between the pathological CUG repeat RNA and the cellular export machinery. These compounds act as bridges that enable the interaction between the otherwise sequestered RNA and the nuclear export factors, facilitating the release of splicing factors and correction of mis-splicing without directly modifying the RNA sequence.
2Ease of operation
If nuclear RNA foci sequester splicing factors, then alternative splicing is disrupted, but no current treatment exists to reverse this effect
Solution Approach 1:
The patent implements self-service by designing compounds that enable the cellular export machinery to naturally process and export the CUG repeat RNA-containing transcripts. The compounds facilitate the recruitment of endogenous export factors to the pathological RNA, allowing the cell's own transport systems to resolve the sequestration problem without requiring external intervention or complex artificial systems.
3Object-affected harmful factors
If CUG repeat expansions cause RNA retention in the nucleus, then transcript accumulation occurs, but promoting nuclear export is needed to reduce toxicity
Solution Approach 1:
The patent applies parameter changes by modifying the physical-chemical properties of the CUG repeat RNA through compound binding. This binding alters the RNA's conformational state and interaction properties, transforming it from a nuclear-retained aggregate-prone form to an export-competent form that can be transported to the cytoplasm, thereby changing the stability parameter of nuclear RNA retention.
Data Source
AI summary
Compounds which inhibit the formation and/or accumulation of RNA foci, such as those due to polynucleotide repeats (e.g., trinucleotide repeats) are described herein. Also described herein are uses of such compounds, such as for the inhibition of the formation and accumulation such RNA foci, as well as for the treatment of polynucleotide repeat disorders (e.g., trinucleotide repeat disorders), such as myotonic dystrophy (e.g., DM1). Such compounds include compounds of formula 1, 1a, 1b, 2, 2a and (3) described herein.